Fintel reports that on June 1, 2023, Needham reiterated coverage of Phreesia (NYSE:PHR) with a Buy recommendation.
Analyst Price Forecast Suggests 33.87% Upside
As of May 11, 2023, the average one-year price target for Phreesia is 40.19. The forecasts range from a low of 30.30 to a high of $48.30. The average price target represents an increase of 33.87% from its latest reported closing price of 30.02.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Phreesia is 361MM, an increase of 28.43%. The projected annual non-GAAP EPS is -1.80.
What is the Fund Sentiment?
There are 467 funds or institutions reporting positions in Phreesia. This is an increase of 56 owner(s) or 13.63% in the last quarter. Average portfolio weight of all funds dedicated to PHR is 0.18%, an increase of 13.45%. Total shares owned by institutions increased in the last three months by 3.94% to 58,634K shares. 
The put/call ratio of PHR is 1.13, indicating a bearish outlook.
What are Other Shareholders Doing?
Brown Advisory holds 3,228K shares representing 6.02% ownership of the company. In it's prior filing, the firm reported owning 3,097K shares, representing an increase of 4.05%. The firm decreased its portfolio allocation in PHR by 54.54% over the last quarter.
T. Rowe Price Investment Management holds 2,696K shares representing 5.03% ownership of the company. In it's prior filing, the firm reported owning 2,677K shares, representing an increase of 0.71%. The firm decreased its portfolio allocation in PHR by 6.09% over the last quarter.
Credit Suisse holds 1,941K shares representing 3.62% ownership of the company. In it's prior filing, the firm reported owning 2,028K shares, representing a decrease of 4.50%. The firm decreased its portfolio allocation in PHR by 78.85% over the last quarter.
PRSVX - T. Rowe Price Small-Cap Value Fund holds 1,683K shares representing 3.14% ownership of the company. In it's prior filing, the firm reported owning 1,686K shares, representing a decrease of 0.20%. The firm increased its portfolio allocation in PHR by 0.58% over the last quarter.
FSMEX - Medical Technology and Devices Portfolio holds 1,670K shares representing 3.12% ownership of the company. In it's prior filing, the firm reported owning 2,000K shares, representing a decrease of 19.76%. The firm increased its portfolio allocation in PHR by 15.06% over the last quarter.
Phreesia Background Information
(This description is provided by the company.)
Phreesia gives healthcare organizations a suite of robust applications to manage the patient intake process. Our innovative SaaS platform engages patients and provides a modern, convenient experience, while enabling our clients to optimize their staffing, boost profitability and enhance clinical care.
Key filings for this company:
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
